Stuart Lind
Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thrombin | 4 | 2020 | 145 | 1.300 |
Why?
| Thrombocytopenia | 2 | 2021 | 186 | 1.120 |
Why?
| Clioquinol | 6 | 2011 | 7 | 1.060 |
Why?
| Docosahexaenoic Acids | 4 | 2014 | 82 | 0.830 |
Why?
| Sinus Thrombosis, Intracranial | 1 | 2021 | 20 | 0.720 |
Why?
| Anticoagulants | 4 | 2018 | 637 | 0.710 |
Why?
| Copper | 3 | 2010 | 108 | 0.640 |
Why?
| Drug Monitoring | 2 | 2018 | 215 | 0.620 |
Why?
| Antithrombins | 2 | 2020 | 58 | 0.590 |
Why?
| Infusions, Parenteral | 1 | 2018 | 38 | 0.580 |
Why?
| Hematologic Tests | 1 | 2017 | 22 | 0.570 |
Why?
| Ionophores | 3 | 2009 | 22 | 0.480 |
Why?
| Zinc | 5 | 2009 | 285 | 0.470 |
Why?
| Antineoplastic Agents | 6 | 2011 | 2046 | 0.450 |
Why?
| Partial Thromboplastin Time | 1 | 2014 | 52 | 0.440 |
Why?
| Thromboplastin | 3 | 2014 | 70 | 0.440 |
Why?
| Vaccination | 1 | 2021 | 1347 | 0.400 |
Why?
| Blood Coagulation | 4 | 2016 | 239 | 0.390 |
Why?
| Ceruloplasmin | 2 | 2009 | 7 | 0.360 |
Why?
| Vitamin B 12 Deficiency | 2 | 2009 | 78 | 0.340 |
Why?
| Algorithms | 1 | 2017 | 1616 | 0.330 |
Why?
| Glutathione Peroxidase | 2 | 2007 | 43 | 0.330 |
Why?
| Oxyquinoline | 1 | 2009 | 3 | 0.320 |
Why?
| Cell Line, Tumor | 16 | 2015 | 3186 | 0.320 |
Why?
| Superoxide Dismutase | 4 | 2012 | 342 | 0.320 |
Why?
| Lead Poisoning | 1 | 2009 | 19 | 0.320 |
Why?
| Factor Xa Inhibitors | 2 | 2025 | 170 | 0.320 |
Why?
| Apoptosis | 8 | 2012 | 2492 | 0.320 |
Why?
| Erythrocyte Membrane | 1 | 2009 | 49 | 0.310 |
Why?
| Lead | 1 | 2009 | 56 | 0.310 |
Why?
| Pyridines | 2 | 2009 | 478 | 0.310 |
Why?
| Metals | 1 | 2009 | 123 | 0.300 |
Why?
| Organometallic Compounds | 1 | 2009 | 106 | 0.300 |
Why?
| Gastrectomy | 1 | 2009 | 102 | 0.290 |
Why?
| Pipecolic Acids | 2 | 2020 | 25 | 0.280 |
Why?
| Hirudins | 2 | 2020 | 53 | 0.270 |
Why?
| Lysosomes | 3 | 2015 | 137 | 0.270 |
Why?
| Metformin | 4 | 2012 | 318 | 0.260 |
Why?
| Neoplasms | 6 | 2011 | 2455 | 0.260 |
Why?
| Heparin | 3 | 2017 | 254 | 0.250 |
Why?
| Annexin A5 | 1 | 2005 | 23 | 0.250 |
Why?
| Coagulants | 1 | 2005 | 15 | 0.250 |
Why?
| Peptide Fragments | 3 | 2020 | 693 | 0.240 |
Why?
| Neurodegenerative Diseases | 1 | 2007 | 113 | 0.240 |
Why?
| Blood Coagulation Tests | 2 | 2016 | 60 | 0.230 |
Why?
| Proteolysis | 3 | 2015 | 167 | 0.230 |
Why?
| Protoporphyrins | 2 | 2015 | 16 | 0.230 |
Why?
| Proteasome Inhibitors | 3 | 2015 | 42 | 0.230 |
Why?
| Rivaroxaban | 2 | 2025 | 252 | 0.220 |
Why?
| Chelating Agents | 3 | 2009 | 68 | 0.220 |
Why?
| Lipid Peroxidation | 4 | 2014 | 151 | 0.210 |
Why?
| Heme Oxygenase-1 | 2 | 2014 | 62 | 0.210 |
Why?
| Cell Survival | 8 | 2012 | 1076 | 0.200 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2014 | 1336 | 0.200 |
Why?
| Recombinant Fusion Proteins | 1 | 2005 | 651 | 0.200 |
Why?
| beta Catenin | 2 | 2015 | 225 | 0.190 |
Why?
| Down-Regulation | 1 | 2004 | 636 | 0.190 |
Why?
| Breast Neoplasms | 7 | 2012 | 2133 | 0.190 |
Why?
| Ovarian Neoplasms | 3 | 2013 | 484 | 0.190 |
Why?
| Humans | 33 | 2025 | 129626 | 0.190 |
Why?
| Venous Thromboembolism | 1 | 2025 | 287 | 0.170 |
Why?
| Signal Transduction | 8 | 2013 | 4931 | 0.170 |
Why?
| Thiones | 2 | 2009 | 14 | 0.160 |
Why?
| Thrombin Time | 2 | 2020 | 11 | 0.160 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1560 | 0.150 |
Why?
| Superoxide Dismutase-1 | 3 | 2012 | 10 | 0.140 |
Why?
| Postoperative Complications | 1 | 2009 | 2477 | 0.140 |
Why?
| Platelet Activation | 1 | 2017 | 91 | 0.140 |
Why?
| Immunoassay | 1 | 2017 | 107 | 0.140 |
Why?
| Arginine | 2 | 2020 | 263 | 0.140 |
Why?
| Blotting, Western | 5 | 2013 | 1206 | 0.130 |
Why?
| Cell Proliferation | 4 | 2012 | 2373 | 0.130 |
Why?
| Catalase | 2 | 2007 | 128 | 0.120 |
Why?
| Recombinant Proteins | 2 | 2020 | 1308 | 0.120 |
Why?
| Serotonin | 1 | 2017 | 318 | 0.120 |
Why?
| Prostatic Neoplasms | 1 | 2003 | 998 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2008 | 432 | 0.120 |
Why?
| Thromboembolism | 1 | 2016 | 112 | 0.120 |
Why?
| Sulfonamides | 2 | 2020 | 497 | 0.120 |
Why?
| Hospitalization | 2 | 2025 | 2057 | 0.110 |
Why?
| Dabigatran | 1 | 2014 | 21 | 0.110 |
Why?
| beta-Alanine | 1 | 2014 | 16 | 0.110 |
Why?
| Fanconi Anemia Complementation Group Proteins | 1 | 2014 | 6 | 0.110 |
Why?
| Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 41 | 0.110 |
Why?
| Wnt Signaling Pathway | 1 | 2015 | 170 | 0.110 |
Why?
| NF-kappa B | 2 | 2008 | 665 | 0.100 |
Why?
| Benzimidazoles | 1 | 2014 | 162 | 0.100 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2011 | 191 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2016 | 2011 | 0.100 |
Why?
| PPAR alpha | 1 | 2012 | 58 | 0.100 |
Why?
| Chromans | 1 | 2012 | 24 | 0.100 |
Why?
| Caspase 3 | 3 | 2012 | 245 | 0.100 |
Why?
| Wnt Proteins | 1 | 2013 | 127 | 0.100 |
Why?
| Receptor, ErbB-2 | 2 | 2011 | 326 | 0.090 |
Why?
| Curcumin | 1 | 2012 | 29 | 0.090 |
Why?
| Receptors, Steroid | 1 | 2012 | 49 | 0.090 |
Why?
| Nitroquinolines | 1 | 2011 | 1 | 0.090 |
Why?
| Mice, Nude | 3 | 2014 | 682 | 0.090 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2012 | 91 | 0.090 |
Why?
| Receptor, IGF Type 1 | 1 | 2011 | 64 | 0.090 |
Why?
| Aged, 80 and over | 3 | 2025 | 7052 | 0.090 |
Why?
| Biomarkers | 2 | 2018 | 3968 | 0.090 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2014 | 808 | 0.090 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 274 | 0.090 |
Why?
| Vitamin E | 2 | 2012 | 120 | 0.090 |
Why?
| STAT3 Transcription Factor | 1 | 2012 | 194 | 0.080 |
Why?
| Drug Synergism | 2 | 2012 | 370 | 0.080 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2012 | 234 | 0.080 |
Why?
| Edetic Acid | 1 | 2009 | 46 | 0.080 |
Why?
| Acetylcysteine | 1 | 2010 | 146 | 0.080 |
Why?
| Buffers | 1 | 2009 | 56 | 0.080 |
Why?
| Citrates | 1 | 2009 | 42 | 0.080 |
Why?
| Cell Cycle | 2 | 2009 | 588 | 0.080 |
Why?
| Adult | 5 | 2025 | 35599 | 0.080 |
Why?
| Protease Inhibitors | 1 | 2009 | 107 | 0.080 |
Why?
| Hydrogen Peroxide | 1 | 2010 | 317 | 0.080 |
Why?
| Ethylenediamines | 1 | 2008 | 6 | 0.080 |
Why?
| Triazenes | 1 | 2008 | 4 | 0.080 |
Why?
| Sodium Chloride | 1 | 2009 | 137 | 0.080 |
Why?
| Caspases | 2 | 2009 | 245 | 0.070 |
Why?
| Plasma | 1 | 2009 | 205 | 0.070 |
Why?
| RNA, Small Interfering | 2 | 2013 | 591 | 0.070 |
Why?
| Therapeutic Human Experimentation | 1 | 1987 | 1 | 0.070 |
Why?
| Ethics | 1 | 1987 | 7 | 0.070 |
Why?
| Ethical Review | 1 | 1987 | 3 | 0.070 |
Why?
| Economics | 1 | 1987 | 11 | 0.070 |
Why?
| Human Experimentation | 1 | 1987 | 12 | 0.070 |
Why?
| Inhibitory Concentration 50 | 1 | 2007 | 86 | 0.070 |
Why?
| Financial Support | 1 | 1987 | 19 | 0.070 |
Why?
| Tumor Cells, Cultured | 2 | 2009 | 943 | 0.070 |
Why?
| Aged | 4 | 2025 | 22061 | 0.060 |
Why?
| Vitamin B 12 | 1 | 2007 | 122 | 0.060 |
Why?
| Poly(ADP-ribose) Polymerases | 3 | 2012 | 94 | 0.060 |
Why?
| Female | 12 | 2025 | 68734 | 0.060 |
Why?
| Transcription Factor RelA | 1 | 2006 | 84 | 0.060 |
Why?
| Factor VIIIa | 1 | 2005 | 4 | 0.060 |
Why?
| Factor X | 1 | 2005 | 25 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2012 | 530 | 0.060 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2005 | 29 | 0.060 |
Why?
| Oxidative Stress | 1 | 2012 | 1266 | 0.060 |
Why?
| Phosphatidylserines | 1 | 2005 | 88 | 0.060 |
Why?
| Cell Growth Processes | 1 | 2005 | 52 | 0.060 |
Why?
| Cisplatin | 1 | 2007 | 299 | 0.060 |
Why?
| Middle Aged | 5 | 2025 | 31136 | 0.060 |
Why?
| Dietary Supplements | 1 | 2009 | 534 | 0.060 |
Why?
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2004 | 13 | 0.060 |
Why?
| Regression Analysis | 1 | 2007 | 997 | 0.060 |
Why?
| Reactive Oxygen Species | 3 | 2012 | 593 | 0.060 |
Why?
| Leiomyosarcoma | 1 | 2004 | 27 | 0.050 |
Why?
| Chromosomes, Human | 1 | 2004 | 41 | 0.050 |
Why?
| MicroRNAs | 1 | 2010 | 679 | 0.050 |
Why?
| Blood Vessels | 1 | 2005 | 187 | 0.050 |
Why?
| Research | 1 | 1987 | 419 | 0.050 |
Why?
| Animals | 5 | 2014 | 35391 | 0.050 |
Why?
| Neovascularization, Pathologic | 1 | 2005 | 296 | 0.050 |
Why?
| Chromosome Aberrations | 1 | 2004 | 147 | 0.050 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2015 | 149 | 0.050 |
Why?
| Prothrombin | 1 | 2003 | 20 | 0.050 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 843 | 0.050 |
Why?
| Cattle | 1 | 2005 | 977 | 0.050 |
Why?
| Pilot Projects | 1 | 2007 | 1592 | 0.050 |
Why?
| Male | 5 | 2025 | 63670 | 0.050 |
Why?
| Hemorrhage | 1 | 2005 | 680 | 0.040 |
Why?
| Biomedical Research | 1 | 1987 | 640 | 0.040 |
Why?
| Mice | 3 | 2009 | 16961 | 0.040 |
Why?
| Hypoglycemic Agents | 1 | 2009 | 1221 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 949 | 0.040 |
Why?
| Case-Control Studies | 1 | 2007 | 3378 | 0.040 |
Why?
| Microscopy, Fluorescence | 2 | 2013 | 399 | 0.040 |
Why?
| Amino Acids | 1 | 2003 | 487 | 0.040 |
Why?
| Phosphorylation | 2 | 2015 | 1713 | 0.040 |
Why?
| Infusions, Intravenous | 1 | 2020 | 399 | 0.040 |
Why?
| Interleukin-6 | 1 | 2003 | 723 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2012 | 398 | 0.040 |
Why?
| Calibration | 1 | 2016 | 140 | 0.030 |
Why?
| Pyridones | 1 | 2016 | 158 | 0.030 |
Why?
| Antioxidant Response Elements | 1 | 2014 | 7 | 0.030 |
Why?
| Protein Transport | 1 | 2015 | 429 | 0.030 |
Why?
| NF-E2-Related Factor 2 | 1 | 2014 | 79 | 0.030 |
Why?
| Prospective Studies | 1 | 2025 | 7135 | 0.030 |
Why?
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2012 | 15 | 0.030 |
Why?
| Pyrazoles | 1 | 2016 | 404 | 0.020 |
Why?
| bcl-Associated Death Protein | 1 | 2012 | 10 | 0.020 |
Why?
| Genes, Reporter | 1 | 2013 | 265 | 0.020 |
Why?
| Aminosalicylic Acids | 1 | 2012 | 5 | 0.020 |
Why?
| Benzenesulfonates | 1 | 2012 | 19 | 0.020 |
Why?
| DNA Primers | 1 | 2013 | 511 | 0.020 |
Why?
| Chromones | 1 | 2011 | 45 | 0.020 |
Why?
| HL-60 Cells | 1 | 2011 | 34 | 0.020 |
Why?
| Ascorbic Acid | 1 | 2012 | 120 | 0.020 |
Why?
| Dasatinib | 1 | 2011 | 54 | 0.020 |
Why?
| Immunoprecipitation | 1 | 2011 | 157 | 0.020 |
Why?
| Trastuzumab | 1 | 2011 | 100 | 0.020 |
Why?
| Thiazoles | 1 | 2011 | 117 | 0.020 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2012 | 182 | 0.020 |
Why?
| Morpholines | 1 | 2011 | 122 | 0.020 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 187 | 0.020 |
Why?
| Enzyme Activation | 1 | 2012 | 813 | 0.020 |
Why?
| 3' Untranslated Regions | 1 | 2010 | 138 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2014 | 1207 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 361 | 0.020 |
Why?
| Microscopy, Confocal | 1 | 2010 | 307 | 0.020 |
Why?
| Base Sequence | 1 | 2013 | 2147 | 0.020 |
Why?
| Ammonium Chloride | 1 | 2009 | 5 | 0.020 |
Why?
| Cathepsin D | 1 | 2009 | 18 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2010 | 481 | 0.020 |
Why?
| Intracellular Membranes | 1 | 2009 | 83 | 0.020 |
Why?
| Cell Membrane Permeability | 1 | 2009 | 82 | 0.020 |
Why?
| Antioxidants | 1 | 2012 | 558 | 0.020 |
Why?
| Young Adult | 1 | 2025 | 12455 | 0.020 |
Why?
| Pyrimidines | 1 | 2011 | 459 | 0.020 |
Why?
| AMP-Activated Protein Kinases | 1 | 2009 | 191 | 0.020 |
Why?
| Biological Transport | 1 | 2009 | 404 | 0.020 |
Why?
| Ethics Committees, Clinical | 1 | 1987 | 4 | 0.020 |
Why?
| Ethics Committees | 1 | 1987 | 4 | 0.020 |
Why?
| Fees and Charges | 1 | 1987 | 10 | 0.020 |
Why?
| Endothelial Cells | 1 | 2012 | 749 | 0.020 |
Why?
| Ethics Committees, Research | 1 | 1987 | 41 | 0.020 |
Why?
| Research Subjects | 1 | 1987 | 42 | 0.020 |
Why?
| Academies and Institutes | 1 | 1987 | 50 | 0.020 |
Why?
| Organizational Policy | 1 | 1987 | 79 | 0.020 |
Why?
| Drug Resistance, Neoplasm | 1 | 2011 | 752 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 757 | 0.020 |
Why?
| Receptors, Estrogen | 1 | 2009 | 422 | 0.020 |
Why?
| Patient Care | 1 | 1987 | 108 | 0.020 |
Why?
| Informed Consent | 1 | 1987 | 166 | 0.020 |
Why?
| Adolescent | 1 | 2025 | 20412 | 0.020 |
Why?
| Treatment Outcome | 1 | 2020 | 10219 | 0.020 |
Why?
| Patients | 1 | 1987 | 169 | 0.020 |
Why?
| Research Personnel | 1 | 1987 | 156 | 0.010 |
Why?
| Pharmaceutical Preparations | 1 | 1987 | 171 | 0.010 |
Why?
| Cell Line | 1 | 2010 | 2784 | 0.010 |
Why?
| Insurance, Health | 1 | 1987 | 267 | 0.010 |
Why?
| Universities | 1 | 1987 | 409 | 0.010 |
Why?
| Data Collection | 1 | 1987 | 650 | 0.010 |
Why?
| Nucleic Acid Hybridization | 1 | 2004 | 189 | 0.010 |
Why?
| Mitochondria | 1 | 2009 | 876 | 0.010 |
Why?
| Hospitals | 1 | 1987 | 637 | 0.010 |
Why?
| Mutation | 1 | 2012 | 3717 | 0.010 |
Why?
| Delivery of Health Care | 1 | 1987 | 898 | 0.010 |
Why?
| United States | 1 | 1987 | 13871 | 0.010 |
Why?
|
|
Lind's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|